UBS Group AG Buys 135,455 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

UBS Group AG increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 457.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 165,098 shares of the biopharmaceutical company’s stock after acquiring an additional 135,455 shares during the quarter. UBS Group AG owned approximately 0.24% of Ultragenyx Pharmaceutical worth $7,649,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Treasurer of the State of North Carolina raised its holdings in shares of Ultragenyx Pharmaceutical by 1.3% in the third quarter. Treasurer of the State of North Carolina now owns 28,613 shares of the biopharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 370 shares during the last quarter. Tudor Investment Corp Et Al raised its holdings in shares of Ultragenyx Pharmaceutical by 118.0% in the third quarter. Tudor Investment Corp Et Al now owns 35,729 shares of the biopharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 19,338 shares during the last quarter. Privium Fund Management B.V. increased its holdings in Ultragenyx Pharmaceutical by 29.6% during the fourth quarter. Privium Fund Management B.V. now owns 106,741 shares of the biopharmaceutical company’s stock worth $4,821,000 after buying an additional 24,400 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Ultragenyx Pharmaceutical by 39.0% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,349 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 2,061 shares during the last quarter. Finally, Ergoteles LLC purchased a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $5,101,000. 93.17% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $49.98 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $33.36 and a 1 year high of $68.68. The firm has a market cap of $3.54 billion, a PE ratio of -4.88 and a beta of 0.94. The company has a 50 day simple moving average of $42.56 and a two-hundred day simple moving average of $42.27.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.97) by ($0.36). Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative return on equity of 149.75%. The company had revenue of $100.50 million for the quarter, compared to the consensus estimate of $103.90 million. During the same quarter in the previous year, the firm earned ($2.19) earnings per share. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -8.4 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 2,012 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $100,600.00. Following the transaction, the insider now directly owns 74,744 shares of the company’s stock, valued at $3,737,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 639 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $43.40, for a total transaction of $27,732.60. Following the transaction, the chief accounting officer now directly owns 15,558 shares of the company’s stock, valued at $675,217.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Richard Pinion sold 2,012 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $100,600.00. Following the transaction, the insider now directly owns 74,744 shares in the company, valued at $3,737,200. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,299 shares of company stock valued at $518,716. 6.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

RARE has been the subject of a number of research analyst reports. 1-800-FLOWERS.COM restated a “maintains” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, May 8th. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, February 3rd. StockNews.com assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, May 18th. They set a “hold” rating for the company. Credit Suisse Group reiterated an “outperform” rating and set a $96.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. Finally, Robert W. Baird increased their target price on shares of Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the stock an “outperform” rating in a research report on Friday, February 17th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.25.

Ultragenyx Pharmaceutical Profile

(Get Rating)

Ultragenyx Pharmaceutical, Inc engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.